Literature DB >> 9449526

p53 represses Sp1 DNA binding and HIV-LTR directed transcription.

J Bargonetti1, A Chicas, D White, C Prives.   

Abstract

The HIV-LTR region contains binding sites for, and is regulated by, a number of transcription factors including Sp1 and NF-kB. The wild-type p53 tumor suppressor protein represses transcription from the HIV-LTR promoter while oncogenic mutant forms of p53 stimulate expression from the HIV-LTR. We have shown previously that wild-type p53 is a site specific DNA binding protein that binds to a region of the SV40 virus which contains GC-box DNA binding sites for the ubiquitously expressed transcription factor Sp1. In this study using DNase I footprinting, we have shown that purified p53 is able to protect the Sp1 binding sites and the adjacent NF-kB site of the HIV-LTR. Furthermore we have demonstrated that when p53 and Sp1 are mixed together both proteins change each other's interaction with DNA. Interestingly, we noted that oncogenic mutant p53 is also able to change the interaction of Sp1 with DNA. We confirmed p53 dependent repression of HIV-LTR driven transcription by comparing the expression from an HIV-LTR reporter construct in the presence and absence of p53. EMSA of an oligonucleotide sequence derived from the HIV-LTR sequence demonstrated a slight decrease in Sp1 DNA binding activity with nuclear extract derived from the cell line expressing a high level of wild-type p53. These data suggest that the influence of p53 on the transcription of promoters with Sp1 binding sites may be partially due to a change in the DNA binding ability of Sp1.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9449526

Source DB:  PubMed          Journal:  Cell Mol Biol (Noisy-le-grand)        ISSN: 0145-5680            Impact factor:   1.770


  25 in total

1.  Divergent regulation of the growth-promoting gene IEX-1 by the p53 tumor suppressor and Sp1.

Authors:  Hee-Jeong Im; Mark R Pittelkow; Rajiv Kumar
Journal:  J Biol Chem       Date:  2002-02-13       Impact factor: 5.157

2.  The tumor suppressor p53 inhibits Net, an effector of Ras/extracellular signal-regulated kinase signaling.

Authors:  Koji Nakade; Hong Zheng; Gitali Ganguli; Gilles Buchwalter; Christian Gross; Bohdan Wasylyk
Journal:  Mol Cell Biol       Date:  2004-02       Impact factor: 4.272

3.  Wild-type p53 controls cell motility and invasion by dual regulation of MET expression.

Authors:  Chang-Il Hwang; Andres Matoso; David C Corney; Andrea Flesken-Nikitin; Stefanie Körner; Wei Wang; Carla Boccaccio; Snorri S Thorgeirsson; Paolo M Comoglio; Heiko Hermeking; Alexander Yu Nikitin
Journal:  Proc Natl Acad Sci U S A       Date:  2011-08-09       Impact factor: 11.205

4.  p73 Interacts with human immunodeficiency virus type 1 Tat in astrocytic cells and prevents its acetylation on lysine 28.

Authors:  Shohreh Amini; Giuseppe Mameli; Luis Del Valle; Anna Skowronska; Krzysztof Reiss; Benjamin B Gelman; Martyn K White; Kamel Khalili; Bassel E Sawaya
Journal:  Mol Cell Biol       Date:  2005-09       Impact factor: 4.272

Review 5.  Mutant p53: one name, many proteins.

Authors:  William A Freed-Pastor; Carol Prives
Journal:  Genes Dev       Date:  2012-06-15       Impact factor: 11.361

Review 6.  p53 mutations in cancer.

Authors:  Patricia A J Muller; Karen H Vousden
Journal:  Nat Cell Biol       Date:  2013-01       Impact factor: 28.824

Review 7.  One function--multiple mechanisms: the manifold activities of p53 as a transcriptional repressor.

Authors:  Levin Böhlig; Karen Rother
Journal:  J Biomed Biotechnol       Date:  2011-03-08

8.  Mutant p53 proteins bind DNA in a DNA structure-selective mode.

Authors:  Thomas Göhler; Stefan Jäger; Gabriele Warnecke; Hideyo Yasuda; Ella Kim; Wolfgang Deppert
Journal:  Nucleic Acids Res       Date:  2005-02-18       Impact factor: 16.971

9.  The β-carboline alkaloid harmine inhibits telomerase activity of MCF-7 cells by down-regulating hTERT mRNA expression accompanied by an accelerated senescent phenotype.

Authors:  Lei Zhao; Michael Wink
Journal:  PeerJ       Date:  2013-10-01       Impact factor: 2.984

Review 10.  The consequence of oncomorphic TP53 mutations in ovarian cancer.

Authors:  Pavla Brachova; Kristina W Thiel; Kimberly K Leslie
Journal:  Int J Mol Sci       Date:  2013-09-23       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.